In this episode of the podcast, Joe Moore interviews the CEO of Mindset Pharma, James Lanthier. Mindset Pharma is a 3-year old biotechnology company built on discovering and developing new psychedelic compounds to be used as medicine for a variety of indications. While the efficacy of the psychedelics we know can’t be denied, the goal of science is to improve, and Lanthier believes optimizing these drugs will make them safer, more predictable, and more palatable for a far greater portion of the population. Lanthier discusses what’s going on at Mindset Pharma; why patents alone will not be sufficient protection from competition; the long game of biotech, psychedelic stocks, and overreaction to slow growth; the Nagoya protocol; mescaline; the need for big pharma and capitalism; the art of formulation; and how microdosing could soon be revolutionized.

The post PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics appeared first on Psychedelics Today.

Previous articleIncannex to Present at the H.C. Wainwright First Annual Mental Health Conference
Next articleDigging Up Druggable Targets: Psilocybin Efficacy in a Model of OCD